| Literature DB >> 27130429 |
Alexandra U Scherrer1, Wan-Lin Yang1, Roger D Kouyos1, Jürg Böni2, Sabine Yerly3, Thomas Klimkait4, Vincent Aubert5, Matthias Cavassini6, Manuel Battegay7, Christoph Hauser8, Alexandra Calmy9, Patrick Schmid10, Enos Bernasconi11, Huldrych F Günthard1.
Abstract
The prevalence of integrase strand transfer inhibitor (INSTI)-transmitted drug resistance (TDR) may increase with the increasing use of INSTIs. We analyzed the prevalence of INSTI TDR in the Swiss HIV Cohort Study (2008-2014). In 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected. Prevalence was stable, although INSTIs were increasingly used. We showed that this is in contrast to the introduction of previous drug classes, in which more treatment failures with resistant strains occurred and TDR was observed more rapidly. We demonstrated on a population-level that it is possible to avoid TDR to a new drug class for years.Keywords: HIV-1 drug resistance; integrase; population viral load; prevalence; transmission of drug resistance
Mesh：
Substances：
Year: 2016 PMID： 27130429 DOI： 10.1093/infdis/jiw165
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226